ReviewCell research2008
Genomic analysis of epithelial ovarian cancer.
Review in Cell research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer.Journal of the National Cancer Institute · 2014Pooled it
- A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study.Gynecologic oncology · 2011Trial
- Liposomal Vitamin C as a Modulator of the Efficacy of Ceralasertib Therapy in Ovarian Cancer.International journal of molecular sciences · 2026Article
- Small extracellular vesicle-based one-step high-throughput microfluidic platform for epithelial ovarian cancer diagnosis.Journal of nanobiotechnology · 2025Article
- Proteomic characterization of epithelial ovarian cancer delineates molecular signatures and therapeutic targets in distinct histological subtypes.Nature communications · 2023Article
- Profiling the metabolome of uterine fluid for early detection of ovarian cancer.Cell reports. Medicine · 2023Article
- Galectin-1 as a predictive biomarker in ovarian cancer.Journal of ovarian research · 2021Article
- Article
- Myeloid-derived suppressor cells promote epithelial ovarian cancer cell stemness by inducing the CSF2/p-STAT3 signalling pathway.The FEBS journal · 2020Article
- NF-κB p65 promotes ovarian cancer cell proliferation and migration via regulating mortalin.Journal of cellular and molecular medicine · 2019Article
- Next-generation sequencing-based genomic profiling analysis reveals novel mutations for clinical diagnosis in Chinese primary epithelial ovarian cancer patients.Journal of ovarian research · 2019Article
- Spectrum and Prevalence of Pathogenic Variants in Ovarian Cancer Susceptibility Genes in a Group of 333 Patients.Cancers · 2018Article
- Clear cell carcinoma of the ovary: Clinicopathologic features and outcomes in a Chinese cohort.Medicine · 2018Observational
- Survival benefit of patients with early-stage ovarian carcinoma treated with paclitaxel chemotherapeutic regimens.Journal of gynecologic oncology · 2018Article
- Highly and moderately aggressive mouse ovarian cancer cell lines exhibit differential gene expression.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Overexpression of S100A14 in human serous ovarian carcinoma.Oncology letters · 2016Article
- The anti-tumor efficacy of 2-deoxyglucose and D-allose are enhanced with p38 inhibition in pancreatic and ovarian cell lines.Journal of experimental & clinical cancer research : CR · 2015Article
- Role of mesenchymal cells in the natural history of ovarian cancer: a review.Journal of translational medicine · 2014Review
- Identification of ribonucleotide reductase M2 as a potential target for pro-senescence therapy in epithelial ovarian cancer.Cell cycle (Georgetown, Tex.) · 2014Article
- HMGA2 and high-grade serous ovarian carcinoma.Journal of molecular medicine (Berlin, Germany) · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Ovarian cancer is a major health problem for women in the United States. Despite evidence of considerable heterogeneity, most cases of ovarian cancer are treated in a similar fashion. The molecular basis for the clinicopathologic characteristics of these tumors remains poorly defined. Whole genome expression profiling is a genomic tool, which can identify dysregulated genes and uncover unique sub-classes of tumors. The application of this technology to ovarian cancer has provided a solid molecular basis for differences in histology and grade of ovarian tumors. Differentially expressed genes identified pathways implicated in cell proliferation, invasion, motility, chromosomal instability, and gene silencing and provided new insights into the origin and potential treatment of these cancers. The added knowledge provided by global gene expression profiling should allow for a more rational treatment of ovarian cancers. These techniques are leading to a paradigm shift from empirical treatment to an individually tailored approach. This review summarizes the new genomic data on epithelial ovarian cancers of different histology and grade and the impact it will have on our understanding and treatment of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.